© Reuters.
REDWOOD CITY, California – Resolution , Inc. (NASDAQ:), a clinical-stage biopharmaceutical company, has announced promising results from a preclinical study indicating that its lead compound, RZ358, could effectively treat hypoglycemia resulting from non-insular cell tumors (NICT) that cause hyperinsulinism. . The study findings suggest a potential to more than double the addressable patient population living with this condition.
The company's recent in vitro pharmacology research evaluated the impact of RZ358 on insulin receptor activation by insulin-like growth factor 2 (IGF-2), compared to insulin, at disease-relevant concentrations. The results demonstrated the ability of RZ358 to mitigate both IGF-2 and insulin signaling, supporting the broad therapeutic applicability of the compound in the treatment of hypoglycemia due to various forms of hyperinsulinism.
Dr. Brian Roberts, Rezolute's chief medical officer, expressed optimism about RZ358's potential to offer significant therapeutic benefits to cancer patients with limited options for managing hypoglycemia, which can complicate cancer treatment. The company had previously reported successful use of RZ358 under its Expanded Access Program for patients with insulin-producing pancreatic islet cell tumors.
Rezolute has engaged with the US Food and Drug Administration (FDA) regarding a potential single-registration study that may include patients with hypoglycemia due to both islet cell tumor hypoglycemia (ICTH) and to NICTH. Inclusion of NICTH patients could significantly expand the market for RZ358 in tumor hyperinsulinism, estimated at approximately 4,500 patients in the US.
RZ358 is a fully human monoclonal antibody targeting an allosteric site on insulin receptors, designed to counteract excess insulin receptor activation and ameliorate hypoglycemia. The compound is also in a Phase 3 trial for congenital hyperinsulinism, a rare pediatric condition in which children overproduce insulin. RZ358 has received orphan drug designation in the US and EU for the treatment of congenital hyperinsulinism, as well as additional designations for use in the treatment of insulinoma.
This announcement is based on a press release and contains forward-looking statements regarding the potential efficacy and therapeutic applications of RZ358. These statements are not guarantees of future performance and are subject to risks and uncertainties.
This article was generated with the support of ai and reviewed by an editor. For more information consult our T&C.
